Risk Stratification Will Guide European Acceptance Of Drug-Coated Stents
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is anticipating slower uptake of drug-coated stents in Europe than in the U.S., with the anti-restenosis therapy to be used only in high-risk patient populations